Mary Caffrey

Chris Christie vowed to devote his final year as New Jersey's governor to fighting opioid abuse. A veteran advocate says Christie has accomplished more than people realize, and his use of the bully pulpit should not be underestimated.

The approval comes a day after the Trump administration released a guidance for states that want to require work from able-bodied Medicaid recipients. Current CMS Administrator Seema Verma designed the Kentucky program when she was a consultant but recused herself from the application.

The same mechanisms that cause those with long-term HIV infection to suffer higher rates of heart attacks or strokes put children born with disease at early risk of cardiovascular disease, according to a new study.

The long-awaited guidance allows states to seek waivers that require able-bodied adults to show they are working, receiving education, serving as a caregiver, volunteering, or receiving substance abuse treatment in order to be eligible for Medicaid.

Brenda Schmidt, CEO of Solera Health, discusses the historic launch of the Medicare Diabetes Prevention Program scheduled for this April and how her company is helping providers and other stakeholders get ready.

The announcement comes after CMS canceled an Obama-era proposal for mandatory bundled payments in cardiac care, as well as a mandatory expansion of a program in joint replacements.

The announcement comes after CMS canceled an Obama-era proposal for mandatory bundled payments in cardiac care, as well as a mandatory expansion of a program in joint replacements.

The study confirms reports heard throughout the country in the years since implementation of the Affordable Care Act.

The factory-calibrated continuous glucose monitoring (CGM) system is being touted as less expensive, and a spokeswoman said it will not require bundling with a meter, which is required for a competitor.

Dexcom Executive Vice President and Chief Commercial Officer RIck Doubleday visited The American Journal of Managed Care® to discuss Medicare reimbursement for the Dexcom G5 and a new partnership with Fitbit.

As 2017 came to close, The American Journal of Managed Care® (AJMC®) asked readers to weigh in on the events they believed had the greatest impact on managed care during the year. As the votes came in, it was clear that what happens in Washington, DC, matters—and that Capitol Hill policy makers will continue to make a difference in 2018.

Adapting payment models to reward outcomes is key to making lifestyle change fit into a managed care framework, several articles find.

The spending bill featured a waiver to avoid Medicare cuts in 2018, before voters to go to the polls in the midterm elections.

A short film supported by the makers of Stiolto Respimat shows the day-to-day life of 3 patients with COPD.

An interview with one of the authors of a large observational study that has seen findings consistent with recent cardiovascular outcomes trials in SGLT2 inhibitors.

A least one US payer, CareMore, has a program to combat loneliness in seniors to prevent chronic disease and other health problems.

Changes to CMS regulations and a post that became a social media phenomenon top the list.

What the CEO of the American Association for the Advancement of Science thinks about the current controversy.

On the plus side, a partnership with the American Medical Association appears to have contributed to a rise in provider referrals to lifestyle modification programs.

The payment reform movement has changed the thinking about what can be done for patients with diabetes and heart failure, for the good of patients.

New companies are finding patients for clinical trials in remote locations and trimming months off the enrollment process.

The cost of insulin has been a major policy issue in recent years. FDA Commissioner Scott Gottlieb, MD, said the approval of a new choice in insulin was a sign of his commitment to giving patients lower-cost options.

Both Don Berwick, MD, MPP, and Jerry Avorn, MD, argue that staying silent in the current climate is a choice, and not a good one for physicians.

The American Diabetes Association update has recommendations that affect liraglutide, canagliflozin, and empagliflozin.

Infantile spasms are hard to diagnose, which can lead to treatment delays, according to the study authors.

Semaglutide, Novo Nordisk’s once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist for type 2 diabetes (T2D), received FDA approval Tuesday, after beating its rival in a head-to-head trial and coming to the approval process with proof of cardiovascular benefits already in hand.

Sanofi’s newest insulin met its primary objective in a large head-to-head trial that compared it with its chief competitor.

Researchers at Duke University found there is substantial room for improvement in providing consumers with ready access to healthcare prices online.